Biopharma
ByIs Pfizer’s $10 Billion Metsera Acquisition at JPM2026 a Defining Move in the Obesity and Cardiometabolic Race?
San Francisco / New York | January 2026 Pfizer has made a decisive strategic move to expand its…
Is Amgen Bolstering Its Oncology Pipeline at JPM 2026 with an $840 Million Dark Blue Therapeutics Acquisition?
Thousand Oaks, U.S. | January 2026 Amgen has expanded its oncology growth strategy with the acquisition of Dark…
Is AbbVie’s $5.6 Billion RemeGen Licensing Deal at JPM2026 a Bet on the Next Wave of Immuno-Oncology?
Chicago, U.S. | January 2026 AbbVie has reinforced its commitment to externally sourced innovation with a major oncology…
Can Amgen’s 2025 Approvals and Launches Strengthen Its Oncology, Cardiovascular, and Bone Health Leadership Into 2026?
Global | January 2026 — Amgen Inc. achieved key milestones in 2025, marked by multiple regulatory approvals, label…
Is Novo Nordisk Facing Legal Scrutiny Over Diabetes Drug Market Conduct?
23 January 2026 Executive Summary Novo Nordisk is facing a new class-action lawsuit in the U.S., filed by…
Is Novo Nordisk’s Oral Wegovy Off to a Record Start? Early Prescription Surge Signals Strong Momentum
23 January 2026 Executive Summary Novo Nordisk’s newly launched oral Wegovy weight-loss therapy has recorded a robust debut,…
